Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States
Rhea-AI Summary
Moolec Science (NASDAQ:MLEC) completed its 2026 commercial planting campaign for the GLASO1 high-GLA safflower program in American Falls, Idaho, within the optimal agronomic window. Fields were planted using soil, irrigation, and seed-conditioning protocols aimed at maximizing emergence and stand establishment.
Moolec reports prior commercial GLA concentrations around 45% and has now identified 52 elite genotypes exceeding 60% GLA on average from 320 candidates, supporting its 2027 commercial expansion and future large-scale production strategy.
Positive
- 2026 GLASO1 commercial planting campaign completed within optimal agronomic window in Idaho
- Prior commercial GLA concentrations reported at approximately 45% from GLASO1 safflower
- Identification of 52 elite genotypes with average GLA concentrations above 60%
- Breeding program supports renewed high-purity seed inventory for future scale-up
- Advancement of GLASO1 platform toward larger-scale commercial execution and 2027 expansion
Negative
- None.
News Market Reaction – MLEC
In the May 14 session, MLEC gained 1.68%, reflecting a mild positive market reaction. Argus tracked a peak move of +16.9% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | GLASO1 industrialization | Positive | +4.5% | Completion of first GLASO1 industrialization phase and 2026 sowing plans. |
| Apr 07 | R&D breakthrough | Positive | -4.8% | Breakthrough expression of bovine myoglobin in pea seeds platform project. |
| Feb 13 | High GLA results | Positive | +69.2% | 2025 GLASO1 campaign delivering ~45% GLA at commercial-scale crushing. |
| Jan 30 | Nasdaq listing terms | Neutral | -17.4% | Nasdaq Panel granting continued listing subject to specific compliance conditions. |
| Jan 23 | Equity exception memo | Positive | -5.1% | Nasdaq Staff memo supporting exception to regain equity compliance by June 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News on GLASO1 operational milestones has previously seen both strong rallies and modest gains, while regulatory/listing updates often drew negative reactions, indicating mixed alignment between news tone and price moves.
Over the past months, Moolec reported several GLASO1 milestones, including a 2025 U.S. campaign with ~45% GLA concentration and strong yields, followed by confirmation of industrialization progress and plans for 2026 sowing on Apr 29, 2026. A molecular farming breakthrough in bovine myoglobin was disclosed on Apr 7, 2026. In parallel, Nasdaq listing compliance and equity exceptions dominated early 2026 headlines. Today’s successful 2026 GLASO planting and higher-GLA genotypes extend this operational trajectory against a backdrop of earlier balance-sheet and listing remediation.
Key Terms
gamma-linolenic acid medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARWICK, GB / ACCESS Newswire / May 14, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the 2026 commercial planting campaign for its GLASO1 safflower program focused on the production of high-GLA ("Gamma-Linolenic Acid") specialty oils for industrial and advanced ingredient applications.
"Today represents a defining moment for Moolec. Regaining compliance with Nasdaq while simultaneously advancing the commercial execution of our GLASO1 platform reflects the extraordinary resilience, discipline, and commitment of our entire team. Over the past quarters, we have worked relentlessly across operations, finance, science, and corporate execution to strengthen the foundations of the Company for the long term. The successful execution of our 2026 commercial planting campaign, together with the continued advancement of our proprietary genetics platform, demonstrates our ability to keep building and executing even during challenging periods. We are also extremely proud of the professionalism and dedication demonstrated by our farming partners in the United States, whose operational expertise and execution capabilities are playing an important role in the continued development of the GLASO platform. We believe the progress achieved across our operational and corporate initiatives positions Moolec for the next phase of scalable commercialization and growth," commented Alejandro Antalich, Chief Executive Officer of Moolec Science.
GLASO Successfully Completes 2026 Commercial Planting Campaign
Commercial planting activities commenced on May 4, 2026, and were successfully completed this week during the optimal agronomic planting window in the American Falls region of Idaho, an area recognized for its favorable conditions for safflower cultivation, including a semi-arid climate, low-humidity environment, well-drained soils, strong solar exposure, and access to established irrigation infrastructure.
The 2026 campaign represents another important operational milestone as GLASO1 continues progressing toward larger-scale commercial execution supported by proprietary genetics, advanced agronomic management, and increasing demand for differentiated specialty oil solutions.
All production fields were planted following extensive soil preparation, irrigation optimization, and seed conditioning protocols designed to maximize germination performance, crop emergence, and stand establishment. Based on current field conditions and forecasted temperatures, the Company expects strong crop establishment during the coming weeks.
Proprietary High-GLA Genetics Program Advances 2027 Commercial Expansion Strategy
In parallel with commercial field operations, Moolec continues advancing its proprietary safflower breeding and genetic selection platform focused on increasing GLA concentration performance, improving genetic purity, and supporting future commercial scale-up initiatives. As previously disclosed by the Company, GLASO1 achieved GLA concentrations of approximately
Moolec believes these results represent a significant advancement in safflower oil composition performance and further reinforce the differentiated profile of the GLASO1 platform within the high-value specialty oils sector. The selected elite lines are expected to be planted individually in dedicated research plots following completion of final seed conditioning procedures. The ongoing breeding program is designed to support the generation of renewed high-purity seed inventory intended to enhance future commercial planting programs and larger-scale production initiatives.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 50 granted and patent applications across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit https://moolecscience.com/ir/.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Moolec Science's Contacts:
Investor Relations inquiries: ir@moolecscience.com
¹ Pat. US 7,893,321 B2 (Application No. 11/438,951) and Pat. US 8,192,964 B2 (Application No. 13/025,345)
SOURCE: Moolec Science SA
View the original press release on ACCESS Newswire